Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accounts Payables: 2019-2024

Historic Accounts Payables for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $5.4 million.

  • Allogene Therapeutics' Accounts Payables fell 32.82% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 32.82%. This contributed to the annual value of $5.4 million for FY2024, which is 8.53% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Accounts Payables is $5.4 million, which was down 8.53% from $5.9 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Accounts Payables ranged from a high of $13.9 million in FY2022 and a low of $5.4 million during FY2024.
  • For the 3-year period, Allogene Therapeutics' Accounts Payables averaged around $8.4 million, with its median value being $5.9 million (2023).
  • Per our database at Business Quant, Allogene Therapeutics' Accounts Payables spiked by 35.45% in 2022 and then tumbled by 57.54% in 2023.
  • Allogene Therapeutics' Accounts Payables (Yearly) stood at $10.4 million in 2020, then dropped by 1.30% to $10.3 million in 2021, then spiked by 35.45% to $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then decreased by 8.53% to $5.4 million in 2024.